MARKET

PLXP

PLXP

PLx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.700
+0.020
+0.54%
Closed 16:00 06/01 EDT
OPEN
3.740
PREV CLOSE
3.680
HIGH
3.786
LOW
3.410
VOLUME
1.40K
TURNOVER
--
52 WEEK HIGH
7.41
52 WEEK LOW
1.800
MARKET CAP
33.88M
P/E (TTM)
-3.4557
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PLXP stock price target is 11.50 with a high estimate of 13.00 and a low estimate of 10.00.

EPS

PLXP News

More
96 Biggest Movers From Yesterday
Gainers Mmtec, Inc. (NASDAQ: MTC) shares climbed 86.4% to close at $2.05 on Tuesday after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 6d ago
LK, ALT, CLBS and BLRX among midday movers
Seeking Alpha - Article · 6d ago
PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing
GlobeNewswire · 05/18 21:30
JMP Securities Maintains Market Outperform on PLx Pharma, Lowers Price Target to $10
JMP Securities maintains PLx Pharma (NASDAQ:PLXP) with a Market Outperform and lowers the price target from $15 to $10.
Benzinga · 05/18 14:41
PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/15 16:12
PLx Pharma Inc. Reports First Quarter 2020 Results
GlobeNewswire · 05/15 11:50
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14)
Benzinga · 05/15 11:49
PLx Pharma Q1 EPS $0.080 Beats $(0.390) Estimate, Sales $2.523K Down From $317.560K YoY
PLx Pharma (NASDAQ:PLXP) reported quarterly earnings of $0.080 per share which beat the analyst consensus estimate of $(0.390) by 120.51 percent. This is a 122.22 percent increase over losses of $(0.360) per share from
Benzinga · 05/15 10:51

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About PLXP

PLx Pharma Inc. is a late-stage specialty pharmaceutical company. The Company is focusing on developing clinically-validated and patent-protected PLxGuard delivery system. The Company’s lead product, Vazalore 325 mg, which is a formulation of aspirin using the PLxGuard delivery system intended to provide antiplatelet for cardiovascular disease prevention as compared to the current standard of care, enteric-coated aspirin, and significantly reduce GI side effects as compared with immediate-release aspirin. Vazalore 325 mg (formerly PL2200 Aspirin 325 mg and Aspertec 325 mg) was approved under the drug name aspirin, and the name Vazalore was granted after the FDA approval. The Company is focused on manufacturing, scale-up and label finalization for Vazalore 325 mg aspirin dosage form and preparing an sNDA for Vazalore 81 mg maintenance dosage form. The Company’s product pipeline also includes other oral non-steroidal anti-inflammatory drugs (NSAIDs).
More

Webull offers kinds of PLx Pharma Inc stock information, including NASDAQ:PLXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLXP stock news, and many more online research tools to help you make informed decisions.